Bristol-Myers Squibb (BMY) option IV into acquiring Karuna Therapeutics (KRTX)
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $56.73 -2.41%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.5%
Revenue Growth %: -4.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.5%
Revenue Growth %: -4.6%
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) 30-day option implied volatility is at 25; compared to its 52-week range of 16 to 26 into acquiring Karuna Therapeutics (KRTX) for $14B.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dataram (DRAM) call put ratio 1.4 calls to 1 put into SK Hynix plans to raise up to $29B
- Intercontinental Exchange (ICE) call put ratio 1 call to 1 put with a focus on July 10 weekly puts as share price near low end of range
- Sandisk (SNDK) call put ratio 1 call to 1.2 puts
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, krtxSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
